O6-(4-bromothenyl)guanine helps overcome drug resistance in breast cancer
Author Information
Author(s): Clemons M, Kelly J, Watson A J, Howell A, McElhinney R S, McMurry T B H, Margison G P
Primary Institution: Cancer Research UK Carcinogenesis Group, Paterson Institute for Cancer Research
Hypothesis
Can O6-(4-bromothenyl)guanine reverse temozolomide resistance in breast cancer cells?
Conclusion
The combination of O6-(4-bromothenyl)guanine and temozolomide significantly delays tumor growth in breast cancer models without increasing toxicity.
Supporting Evidence
- PaTrin-2 effectively inactivated MGMT in MCF-7 cells.
- The combination of PaTrin-2 and temozolomide increased sensitivity to temozolomide by 40 times.
- Complete MGMT inactivation was observed in xenografts within 2 hours of dosing with PaTrin-2.
Takeaway
This study found that a special drug can help another cancer drug work better in breast cancer by making the cancer cells more sensitive to it.
Methodology
The study used MCF-7 breast cancer cells and xenografts in mice to test the effects of O6-(4-bromothenyl)guanine on MGMT activity and temozolomide sensitivity.
Limitations
The study was conducted in animal models, which may not fully replicate human responses.
Participant Demographics
The study involved male nude mice and human breast cancer cell lines.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website